Skip to content Skip to footer
Subscribe Now
NEWS

Royalty Pharma Inks ~$425M Deal with Neurimmune to Acquire Royalty Interest in AstraZeneca’s Cliramitug

Shots: Royalty Pharma will pay Neurimmune up to $425M, incl. $125M upfront, in exchange for a 3% to 4% royalty on worldwide net sales of AstraZeneca’s cliramitug Royalty Pharma will pay Neurimmune an additional $125M in cash in Q1’27, with the remaining $175M contingent on the achievement of specified clinical & regulatory milestones Cliramitug is…
July 23, 2026

Read more

NEWS

Repligen to Acquire BioLife for ~$1.5B

Shots: Repligen has entered into a definitive agreement to acquire BioLife Repligen will acquire BioLife for an enterprise value of ~$1.5B, with BioLife stockholders receiving $11.25 per share in cash plus 0.1442 Repligen shares, representing total consideration of $31/share, comprising 64% stock & 36% cash Acquisition is expected to fast-track Repligen’s leadership & customer solutions…
July 23, 2026

Read more

NEWS

GSK Reports the US FDA Approval of Jideytro for Previously Treated ROS1-Positive NSCLC

Shots: The US FDA has approved Jideytro (zidesamtinib) for the treatment of adults with locally advanced or metastatic ROS1-positive NSCLC who received a prior ROS1 kinase inhibitor Approval was based on the global P-I/II (ARROS-1) trial evaluating Jideytro in pts (n=117) with advanced or metastatic ROS1-positive NSCLC previously treated with a ROS1 inhibitor Trial showed meaningful & durable…
July 23, 2026

Read more

NEWS

Jupiter Neurosciences Inks ~$100M Deal with PharmAla Biotech for Exclusive US Rights to ALA-002

Shots: Jupiter Neurosciences has entered into a definitive license agreement with PharmAla Biotech for perpetual exclusive US rights to ALA-002, a FDA NCE-designated, non-racemic MDMA formulation Jupiter Neurosciences will receive perpetual exclusive US rights to ALA-002 for $3.3M upfront ($1.5M cash + $1.8M JUNS common stock), with the deal valued at up to $100M, incl.…
July 22, 2026

Read more

NEWS

IMUNON Reports P-II MRD Trial Data on IMNN-001 for Newly Diagnosed Advanced Ovarian Cancer

Shots: IMUNON has reported preliminary data from its ongoing P-II MRD trial assessing IMNN-001 (intraperitoneally) in combination with SoC neoadj. & adj. CT (N/ACT) + Avastin, in women with newly diagnosed advanced ovarian cancer Data from nine pts per arm reaching second-look laparoscopy showed IMNN-001 achieved deeper antitumor responses than control, with lower MRD positivity…
July 22, 2026

Read more

NEWS

Myriad Genetics Launches FirstGene Multi-Screen Prenatal Test in the US

Shots: Myriad Genetics has commercially launched FirstGene Multiple Prenatal Screen, combining four prenatal genetic screens in a single blood draw as early as 8wks. gestation FirstGene covers common chromosomal conditions, 19 recessive fetal conditions, 20 maternal carrier conditions, & fetal RhD status, with >98% analytical sensitivity & >99% specificity, and results available in ~10 days;…
July 22, 2026

Read more

Innate Pharma
NEWS

Innate Pharma Completes Enrollment in P-I Dose Escalation Study of IPH4502

Shots: Innate Pharma completed enrollment in the P-I (IPH4502-101) dose-escalation study of IPH4502, its Nectin-4 exatecan ADC, enrolling 76 pts across France & the US, incl. those with UC, NSCLC, HNSCC, breast, ovarian, gastric, esophageal, & colorectal cancers Trial is evaluating the safety, tolerability, & preliminary antitumor activity of IPH4502 monotx. in advanced Nectin-4–expressing…
July 22, 2026

Read more

NEWS

NMPA Accepts Junshi Biosciences’ Toripalimab + CT Supplemental Filing for Resectable Stage II–III NSCLC

Shots: NMPA has accepted the supplemental application of toripalimab + Pt-containing CT as perioperative treatment & subsequent monotx. as adj. therapy for the treatment of adult pts with resectable stage II-III NSCLC Filing was based on P-III (NEOTORCH) trial (n=501), which showed perioperative toripalimab + CT met 1EP of improved EFS by 60% (mEFS: not reached…
July 22, 2026

Read more

Load more